Recent

% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

  • alanisstillhere alanisstillhere Jun 16, 2011 4:38 PM Flag

    Fib 38 retrace of move from 1162 to 2145 means

    $17.70 or thereabouts, ie back to aprox. low of the year.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • observer_of_th_obvious observer_of_th_obvious Jun 17, 2011 11:24 AM Flag

      chartnuts, you always try to change what you have said when you are proven to be a liar. Don't you realize there is a permanent record of what you really said?

      First you said, "I first came over to this board in early 2007."

      Now you are trying to change history and make people believe you actually said, "this wasn't my home board until early 2007."

      Nothing will change the fact that you said, "I first came over to this board in early 2007," and were proven be be lying yet again.

      Why do you post these lies?

      I am beginning to believe that you really do have some sort of memory problem, such as Alzheimer's, at work.

    • My home board in 2006 was Biovail (BVF) and continued to be until January 2007. At that time, I lost a Loser Leaves Board bet over there and almost at the same time, Mexie disappeared over here.

      I did post at times over here in 2006 just like in 2003, 2004 and 2005 but this wasn't my home board until early 2007.

    • detox_guys_w_da_strait_jacket detox_guys_w_da_strait_jacket Jun 17, 2011 10:58 AM Flag

      > you still claim you were not posting on the PFE board when Vioxx was withdrawn?... you were NOT posting on the PFE board prior to Torcetrapib being cancelled?


      Absolutely amazing.


      His brain has rotted away to nothing.

    • Seriously, you still claim you were not posting on the PFE board when Vioxx was withdrawn?

      Torcetrapib was cancelled by Pfizer in December, 2006.

      Are you seriously telling people you were NOT posting on the PFE board prior to Torcetrapib being cancelled?

      Seriously? You did not post here before the Torcetrapib cancellation?

    • > For whatever reason, he left just as soon as Yahoo changed its format at the beginning of 2007. That's when I left the BVF board for good


      You left the BVF board "for good" when people insisted that you quite welshing on your "leave the board" bet. You have lost a lot of them...

    • 2007?

      ==================================
      Re: One ugly-mugly chart! Resistance a

      by: chartness2003 (63/M/Los Angeles, Calif.)

      Long-Term Sentiment: Strong Buy

      I say up 75 cents to $1.50 the day that earnings are released - July 19 or 20.
      ==================================


      Senility. It has to be.

    • 2007?

      ======================================================================
      Re: Hank at Goldman Sachs, link (1 Rating) 18-Jun-06 , 05:03 am

      Responding to performer:

      Here is an excerpt from your post:


      1) Confirmed forecast of $13 billion in worldwide Lipitor sales despite their disappointment in the lost of market share.


      I'm not terribly surprised that they confirmed given the highly-favorably currency outlook the rest of the way and the favorable court decision about allowing only one generic Zocor challenger until Dec. 23 which should forestall Lipitor defections.

      With the unfavorable currency translations in Q1-06, Lipitor got off to a slow start for the year - with constant-dollar revenues of $3.2B knocked down to reported revenues of $3.11B.

      In order to get to $13.0B for the year, the statin would have to average $3.3B for the remaining three quarters.

      Since generic Zocor will have SOME effect in the second half, I would have to think that at least $3.3B would need to be seen in Q2 if the $13.0B for the year is to be realistic. This is very late in the quarter - so if Hank is still talking about $13.0B for the year, I have to think that $3.3B in reported revenues for the quarter is about the minimum that he now foresees.

      Why this is so important is that in Q2-05, there were very weak results for Lipitor - only $2.86B in worldwide sales. So if $3.3B for Q2-06 shouldn't be missed by much, just LOOK at this Lipitor comparison:

      $3.30B for Q2-06
      $2.86B for Q2-05

      With all of the negative articles and talk about generic Zocor and June 23, how many analysts and investors are realistically expecting to see a FIFTEEN percent jump in Lipitor revenues over the June quarter of '05?

      Imagine what that will do for the stock if those results come out on July 19 and then Hank reiterates $13.0B.

      I'm going to very seriously consider buying up a batch of something like the August 22.50-strike calls a few days before that earnings release. There ought to be a pretty hefty jump in the shares when that Lipitor comparison is seen. NOBODY is expecting to see a 15% gain over last year. And yet it appears like it actually may be in the cards.


      Sentiment : Strong Buy
      You have rated

      chartness2...
      63/Male
      Los Angeles...

    • > I first came over to this board in early 2007.

      =============================================
      Re: Avg. price of $23.47 last 32 session (Not rated) 4-Jul-06 10:06 pm

      On average they will be buying about 8 million shares a week. Only two weeks remain before earnings are released. And those earnings figure to be mighty good compared with the expectations.

      How can they not be when the analysts just sit there despite all kinds of favorable developments. For example,

      1) The euro goes up by 6% this quarter which will raise total revenues by about $340M and earnings by about three cents a share and the analysts just sit there.

      2) Pfizer annnounced that they would buy back $1B in shares in Q2 which hadn't previously been anticipated - and the analysts just sit there.

      3) The company announces that there will be $5B in buybacks in the second half whereas none had previously been expected - and the analysts just sit there.

      4) The company announces that it will vigorously compete with Teva for the generic Zoloft business the rest of the year. That certainly would have to raise revenue expectations and boost earnings a bit as well. But the analysts just sit there.

      A Federal District Court severely restricts generic Zocor competition the rest of the year - something that certainly has to help Lipitor - and the analysts just sit there.

      The you have Hank waxing a lot more optimistic on Lipitor at the June 13 Goldman conference. It has no effect on the analysts though and isn't even reported in the financial press.

      Under the circumstances, I would be most surprised if Q2 earnings didn't beat the estimates handily - with a double-digit revenue comparison for Lipitor - something that few are expecting.

      With such low expectations being fostered by the media, the actual results are bound to provide a nice lift for the stock. I'll be buying August call options for a trade as earnings release date draws near.


      chartness2003

    • > I first came over to this board in early 2007.


      ==================================
      Re: Chart talk (1 Rating) 2-Jul-06 02:15 pm

      What counts is NOW - not what happened when the stock was at 45 times earnings and yielding 0.9% which was the situation when Hank first took over.

      Aside from MO six years ago, I can't think of another big-cap stock that sold at not only a ridiculously-low PE but also a top-notch dividend yield as well. Right now for example, HD is also ridiculously low in terms of PE but their dividend is only 1.7%.

      But when a stock has BOTH the kind of PE AND dividend yield that Pfizer has, the only direction the stock can go is up barring some kind of travesty.

      It's mighty lame when your only comeback is what the stock did when it was grotesquely overpriced. There are limits to all things and we saw the lows on June 23 with a perfect storm of negative events. That's as bad as it gets.

      The almost-certain beat of the analyst consensus on July 19 will send Pfizer surging ahead as market participants just haven't been conditioned to expect that - especially the double-digit favorable Lipitor comparison with a year ago.

      All of the pessimism and negativity held the stock down but those same extremely-low expectations will send it rocketing higher in two-and-a-half weeks.

      chartness2003
      ====================================

      " There are limits to all things and we saw the lows on June 23 with a perfect storm of negative events. That's as bad as it gets."

      " There are limits to all things and we saw the lows on June 23 with a perfect storm of negative events. That's as bad as it gets."

    • So there was a rare post by me on this board at that time. It's just like me posting once in a blue moon on the INTC or ABT boards, etc. now.

      My home base at that time was strictly Tyco and would remain that way until at least 11/17/04 when I cashed out all of my Tyco investments except one. I wanted to move to the PFE board but because of Mexie, I went over to the board of my #2 investment at the time, Biovail (BVF). That was to remain my base until early 2007.

    • View More Messages
 
PFE
32.71-0.20(-0.61%)Apr 29 4:01 PMEDT